Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma

Biomedical Chromatography

Volumn 19, Issue 5, 2005, Pages 394-401

  Pistos, Constantinos ^a   Koutsopoulou, Maria ^a   Panderi, Irene ^b  

^a Independent Research and Laboratory Solutions   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Glimepiride; Human plasma; Mass spectrometry; Pharmacokinetic

Indexed keywords

ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; PARTICLE SIZE; PHARMACOKINETICS; PLASMA (HUMAN);

BIOANALYTICAL; CHLOROBUTANES; GLIMEPIRIDE; HUMAN PLASMAS; ISOPROPANOL; LIQUID-LIQUID EXTRACTION; PHARMACOKINETIC STUDIES; SPECTROMETRIC METHODS; TANDEM MASS SPECTROMETRIC; VALIDATION RESULTS;

MASS SPECTROMETRY;

2 PROPANOL; ACETIC ACID ETHYL ESTER; ACETONITRILE; BUTANE; FORMIC ACID; GLIMEPIRIDE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HUMAN; LIQUID LIQUID EXTRACTION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; STUDENT T TEST; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 22244476388     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.465     Document Type: Article

References (27)

1. Altinöz S and Tekeli D. Analysis of glimepiride by using derivative UV spectrophotometric method. Journal of Pharmaceutical and Biomedical Analysis, 2001; 24: 507-515.
2. Badian M, Korn A, Lehr KH, Malerczyk V and Waldhäusl W. Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea. International Journal of Clinical Pharmacological Therapy and Toxicology 1992; 30(11): 481-482.
3. Badian M, Korn A, Lehr KH, Malerczyk V and Waldhäusl W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug Metabolism, Drug International 1994; 11(4): 331-339.
4. Brian WR. Hypoglycemic agents In Metabolic Drug Interactions, Levy HR, Thummel KE, Trager WF, Hansten PD and Eichelbaum M (eds). Lippincott Williams & Willkins, Philadelphia, PA, 2000; 529-543.
5. CPMP. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Committee for Proprietary Medicinal Products: London, 1998.
6. Draeger E. Clinical profile of glimepiride, Diabetes Research and Clinical Practice 1995; 28(suppl.): 139-146.
7. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E and Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Hormone Metabolism Research 1996; 28(9): 419-425.
8. Eckert HG, Kellner HM, Gantz D, Jantz H, Hornke I and Puttkamer GD. Pharmacokinetics and metabolism of glimepiride. Clinical Reports 1993; 27: 61-92.
9. Geisen K. Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung 1988; 38(8): 1120.
10. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology 2001; 52: 349-355.
11. ICH Topic Q2B, Pharmaeuropa 1996; 8: 108.
12. Jemal M. High-throughput quantitative bioanalysis by LC-MS/MS. 2000; 14: 422-429.
13. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J and Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes 1984; 32: 346-354.
14. Lehr KH and Damm P. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. Journal of Chromatography 1990; 526: 497-505.
15. Malerczyk V, Badian M, Korn A, Lehr KH and Waldhäusl W. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metabolism, Drug International 1994; 11(4): 341-357.
16. Mauer HH, Kratzsch C, Kraemer T, Peters FT and Weber AA. Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2002; 773(1): 63-73.
17. Miners JO and Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology 1998; 45: 525-538.
18. Müller G and Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Hormone Metabolism Research 1996; 28(9): 469-487.
19. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clinical Pharmacology and Therapy 2001; 69(4): 194-200.
20. Niessen WMA. Liquid Chromatography - Mass Spectrometry. Chromatographic Science Series, vol. 79. Marcel Dekker: New York, 1999; 405-459.
21. Pearson JG. Glimepiride. A review of its use in the management of type II diabetes mellitus. Drugs 1998; 55: 563-584.
22. Physicians Desk Reference, 55th edn. Medical Economics: Montvale, NJ, 2001; 678.
23. Pistos C, Astraka C, Kalovidouris M, Vassilopoulos E and Koutsopoulou M. Bioequivalence Evaluation of two brands of glimepiride 4 mg tablets in healthy human volunteers. International Journal of Clinical Pharmacology and Therapeutics 2004 (in press).
24. Ratheiser K, Korn A, Waldhausl W, Komjati M, Vierhapper H, Badian M and Malerczyk V. Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. Arzneimittelforschung 1993; 43: 856-858.
25. Salem II, Idrees J and Al Tamini JI. Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatography B 2004; 799: 103-109.
26. Smyth WF. Electrospray ionisation mass spectrometric behaviour of selected drugs and their metabolites. Analytica Chimica Acta 2003; 492: 1-16.
27. Sonenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, Dechemey GS, Mullican WS, Stonesifer LD. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. The Annals of Pharmacotherapy 1997; 31(6): 671-676.